Short Interest in Boston Scientific Corporation (NYSE:BSX) Expands By 74.4%

Key Points

• Boston Scientific’s short interest surged 74.4% to 48.17 million shares as of August 31, representing 3.3% of shares outstanding and a short-interest ratio of 2.3 days.
• Company insiders bought approximately $9.4 million of stock over the past 90 days, including significant purchases by CEO Michael Mahoney and director David Habiger. Institutional investors own 89.07% of the shares.
• BSX shares traded near $43.97, while analysts maintained a “Moderate Buy” consensus with an average price target of $71.46. The company recently beat quarterly earnings and revenue estimates, reporting $0.86 EPS and $5.44 billion in revenue.

Boston Scientific Corporation (NYSE:BSX - Get Free Report) saw a large growth in short interest in August. As of August 31st, there was short interest totaling 48,173,758 shares, a growth of 74.4% from the August 15th total of 27,617,554 shares. Currently, 3.3% of the shares of the stock are short sold. Based on an average daily volume of 21,036,931 shares, the short-interest ratio is currently 2.3 days.

Insiders Place Their Bets

In other Boston Scientific news, Director David Habiger bought 2,100 shares of the company's stock in a transaction dated Wednesday, August 5th. The stock was acquired at an average price of $47.59 per share, with a total value of $99,939.00. Following the completion of the acquisition, the director directly owned 17,160 shares of the company's stock, valued at $816,644.40. This represents a 13.94% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Michael Mahoney purchased 186,240 shares of the stock in a transaction that occurred on Monday, August 3rd. The shares were acquired at an average price of $48.33 per share, for a total transaction of $9,000,979.20. Following the completion of the transaction, the chief executive officer directly owned 1,590,024 shares of the company's stock, valued at $76,845,859.92. The trade was a 13.27% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Insiders have acquired a total of 194,522 shares of company stock valued at $9,385,210 in the last 90 days. 0.34% of the stock is owned by insiders.

Institutional Trading of Boston Scientific

Institutional investors and hedge funds have recently bought and sold shares of the business. SkyView Investment Advisors LLC acquired a new position in Boston Scientific in the 2nd quarter worth $107,000. Bullseye Investment Management LLC acquired a new stake in Boston Scientific during the 2nd quarter valued at approximately $41,000. Rench Wealth Management Inc. increased its holdings in Boston Scientific by 27.5% during the 2nd quarter. Rench Wealth Management Inc. now owns 27,952 shares of the medical equipment provider's stock worth $1,193,000 after purchasing an additional 6,033 shares during the last quarter. Sequoia Financial Advisors LLC increased its holdings in Boston Scientific by 2.3% during the 2nd quarter. Sequoia Financial Advisors LLC now owns 49,355 shares of the medical equipment provider's stock worth $2,106,000 after purchasing an additional 1,119 shares during the last quarter. Finally, Tidal Investments LLC raised its position in shares of Boston Scientific by 29.2% in the 2nd quarter. Tidal Investments LLC now owns 294,851 shares of the medical equipment provider's stock valued at $12,584,000 after purchasing an additional 66,582 shares in the last quarter. 89.07% of the stock is currently owned by hedge funds and other institutional investors.

Boston Scientific Trading Up 0.2%

Shares of Boston Scientific stock traded up $0.10 on Wednesday, reaching $43.97. The company had a trading volume of 28,465,830 shares, compared to its average volume of 18,642,408. The firm's 50 day moving average price is $46.97 and its two-hundred day moving average price is $54.10. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.74 and a current ratio of 1.24. Boston Scientific has a 52-week low of $42.20 and a 52-week high of $105.65. The firm has a market cap of $63.72 billion, a PE ratio of 17.80, a PEG ratio of 1.04 and a beta of 0.57.

Boston Scientific (NYSE:BSX - Get Free Report) last posted its quarterly earnings data on Wednesday, July 29th. The medical equipment provider reported $0.86 earnings per share for the quarter, topping analysts' consensus estimates of $0.83 by $0.03. The firm had revenue of $5.44 billion during the quarter, compared to analysts' expectations of $5.38 billion. Boston Scientific had a net margin of 17.50% and a return on equity of 19.28%. The firm's quarterly revenue was up 7.5% on a year-over-year basis. During the same quarter last year, the company posted $0.75 EPS. Boston Scientific has set its Q3 2026 guidance at 0.800-0.820 EPS and its FY 2026 guidance at 3.280-3.320 EPS. Sell-side analysts predict that Boston Scientific will post 3.29 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of analysts have issued reports on BSX shares. Truist Financial cut their target price on Boston Scientific from $62.00 to $57.00 and set a "buy" rating for the company in a research note on Thursday, July 30th. Zacks Research lowered shares of Boston Scientific from a "hold" rating to a "strong sell" rating in a report on Friday, June 5th. Citigroup reduced their target price on shares of Boston Scientific from $70.00 to $61.00 and set a "buy" rating on the stock in a research note on Thursday, July 30th. Evercore set a $65.00 target price on shares of Boston Scientific in a report on Monday, July 6th. Finally, Oppenheimer dropped their price target on shares of Boston Scientific from $90.00 to $85.00 and set an "outperform" rating for the company in a research note on Monday, July 27th. Twenty-four investment analysts have rated the stock with a Buy rating, five have issued a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $71.46.

About Boston Scientific

Boston Scientific Corporation is a medical device company that develops, manufactures and markets products used in minimally invasive procedures. Its technologies are designed to diagnose and treat a range of medical conditions while supporting less invasive alternatives to traditional surgery.

The company's products address cardiovascular, endoscopy, urology, pelvic health and neuromodulation applications. Its portfolio includes devices used in cardiac rhythm management and electrophysiology, structural heart procedures, peripheral and vascular interventions, gastrointestinal procedures, kidney stone and prostate treatments, and therapies for chronic pain and other neurological conditions.

Founded in 1979, Boston Scientific serves healthcare providers and patients in markets around the world.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.